Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 5 of 5 for “"dose-limiting toxicity (DLT)"”.

  1. Modified 3+3 Design for MTD Re-estimation

    … clinical trial design is one of the most popular dose-finding designs used in phase I oncology trials to identify the maximum tolerated dose (MTD) for new treatment regimens. While this design is widely used due to its simplicity , it has some notable limitations, including a maximum of six …

    iupui Repository record for Modified 3+3 Design for MTD Re-estimation (opens in a new tab)

  2. Dual-Criterion Dose Finding Designs for Phase I Clinical Trials

    … tolerability of novel therapeutics. Conventional dose escalation methods identify the maximum tolerated dose (MTD) based on dose-limiting toxicity (DLT). However, as cancer therapies have evolved from chemotherapy to targeted therapies, these traditional methods have become problematic. Many …

    uthsc Repository record for Dual-Criterion Dose Finding Designs for Phase I Clinical Trials (opens in a new tab)

  3. Bayesian Phase I Dose Finding In Cancer Trials

    <p>This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: the alternative Bayesian dose-escalation rules, a design based on a time-to-dose-limiting toxicity (DLT) model, and a design based on a discrete-time multi-state (DTMS) model.</p> <p>We list …

    uthsc Repository record for Bayesian Phase I Dose Finding In Cancer Trials (opens in a new tab)

  4. Bayesian Semi-Mechanistic Dose-Finding Designs For Phase I Oncology Trials

    … In oncology, despite the great advances in novel dose-finding designs, the high failure rates of clinical cancer drug development from phase I to III trials call for further improvements on novel designs, in addition to the need to promote and adopt novel designs in practice. Because anticancer …

    uthsc Repository record for Bayesian Semi-Mechanistic Dose-Finding Designs For Phase I Oncology Trials (opens in a new tab)

  5. An Innovative Phase I Trial Design Allowing For The Identification of Multiple Potential Maximum to lerated Doses With Combination Therapy of Targeted Agents

    … to different agents, and 3) higher achievable dose intensity by exploiting non-overlapping toxicities to the host. Even if the toxicity profile of each agent of a given combination is known, the toxicity profile of the agents used in combination must be established. Thus, caution is required …

    uthsc Repository record for An Innovative Phase I Trial Design Allowing For The Identification of Multiple Potential Maximum to lerated Doses With Combination Therapy of Targeted Agents (opens in a new tab)